Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 13:23:09 UTC |
---|
Update Date | 2021-09-26 23:08:01 UTC |
---|
HMDB ID | HMDB0254194 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Lucitanib |
---|
Description | Lucitanib, also known as e-3810 amine, belongs to the class of organic compounds known as naphthalenecarboxamides. Naphthalenecarboxamides are compounds containing a naphthalene moiety, which bears a carboxylic acid amide group at one or more positions. Naphthalene is a bicyclic compound that is made up of two fused benzene rings. Based on a literature review a significant number of articles have been published on Lucitanib. This compound has been identified in human blood as reported by (PMID: 31557052 ). Lucitanib is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Lucitanib is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | CNC(=O)C1=C2C=CC(OC3=C4C=C(OC)C(OCC5(N)CC5)=CC4=NC=C3)=CC2=CC=C1 InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30) |
---|
Synonyms | Value | Source |
---|
e-3810 Amine | ChEBI | e-3810co-3810S 80881AL-3810lucitanib | ChEMBL |
|
---|
Chemical Formula | C26H25N3O4 |
---|
Average Molecular Weight | 443.503 |
---|
Monoisotopic Molecular Weight | 443.184506297 |
---|
IUPAC Name | 6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-N-methylnaphthalene-1-carboxamide |
---|
Traditional Name | 6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-N-methylnaphthalene-1-carboxamide |
---|
CAS Registry Number | Not Available |
---|
SMILES | CNC(=O)C1=C2C=CC(OC3=C4C=C(OC)C(OCC5(N)CC5)=CC4=NC=C3)=CC2=CC=C1 |
---|
InChI Identifier | InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30) |
---|
InChI Key | CUDVHEFYRIWYQD-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as naphthalenecarboxamides. Naphthalenecarboxamides are compounds containing a naphthalene moiety, which bears a carboxylic acid amide group at one or more positions. Naphthalene is a bicyclic compound that is made up of two fused benzene rings. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Naphthalenes |
---|
Sub Class | Naphthalenecarboxylic acids and derivatives |
---|
Direct Parent | Naphthalenecarboxamides |
---|
Alternative Parents | |
---|
Substituents | - 1-naphthalenecarboxamide
- Diaryl ether
- Quinoline
- Anisole
- Alkyl aryl ether
- Pyridine
- Heteroaromatic compound
- Amino acid or derivatives
- Carboxamide group
- Secondary carboxylic acid amide
- Carboxylic acid derivative
- Ether
- Azacycle
- Organoheterocyclic compound
- Organic oxygen compound
- Primary aliphatic amine
- Amine
- Hydrocarbon derivative
- Organic nitrogen compound
- Organic oxide
- Organonitrogen compound
- Organooxygen compound
- Primary amine
- Organopnictogen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Lucitanib,1TMS,isomer #1 | CNC(=O)C1=CC=CC2=CC(OC3=CC=NC4=CC(OCC5(N[Si](C)(C)C)CC5)=C(OC)C=C34)=CC=C12 | 4140.1 | Semi standard non polar | 33892256 | Lucitanib,1TMS,isomer #1 | CNC(=O)C1=CC=CC2=CC(OC3=CC=NC4=CC(OCC5(N[Si](C)(C)C)CC5)=C(OC)C=C34)=CC=C12 | 4143.2 | Standard non polar | 33892256 | Lucitanib,1TMS,isomer #1 | CNC(=O)C1=CC=CC2=CC(OC3=CC=NC4=CC(OCC5(N[Si](C)(C)C)CC5)=C(OC)C=C34)=CC=C12 | 5601.1 | Standard polar | 33892256 | Lucitanib,1TMS,isomer #2 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N)CC1 | 4102.2 | Semi standard non polar | 33892256 | Lucitanib,1TMS,isomer #2 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N)CC1 | 3980.3 | Standard non polar | 33892256 | Lucitanib,1TMS,isomer #2 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N)CC1 | 5594.6 | Standard polar | 33892256 | Lucitanib,2TMS,isomer #1 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N[Si](C)(C)C)CC1 | 4071.1 | Semi standard non polar | 33892256 | Lucitanib,2TMS,isomer #1 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N[Si](C)(C)C)CC1 | 4105.5 | Standard non polar | 33892256 | Lucitanib,2TMS,isomer #1 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N[Si](C)(C)C)CC1 | 5142.2 | Standard polar | 33892256 | Lucitanib,2TMS,isomer #2 | CNC(=O)C1=CC=CC2=CC(OC3=CC=NC4=CC(OCC5(N([Si](C)(C)C)[Si](C)(C)C)CC5)=C(OC)C=C34)=CC=C12 | 4209.6 | Semi standard non polar | 33892256 | Lucitanib,2TMS,isomer #2 | CNC(=O)C1=CC=CC2=CC(OC3=CC=NC4=CC(OCC5(N([Si](C)(C)C)[Si](C)(C)C)CC5)=C(OC)C=C34)=CC=C12 | 4213.6 | Standard non polar | 33892256 | Lucitanib,2TMS,isomer #2 | CNC(=O)C1=CC=CC2=CC(OC3=CC=NC4=CC(OCC5(N([Si](C)(C)C)[Si](C)(C)C)CC5)=C(OC)C=C34)=CC=C12 | 5416.4 | Standard polar | 33892256 | Lucitanib,3TMS,isomer #1 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N([Si](C)(C)C)[Si](C)(C)C)CC1 | 4160.6 | Semi standard non polar | 33892256 | Lucitanib,3TMS,isomer #1 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N([Si](C)(C)C)[Si](C)(C)C)CC1 | 4143.0 | Standard non polar | 33892256 | Lucitanib,3TMS,isomer #1 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N([Si](C)(C)C)[Si](C)(C)C)CC1 | 5000.9 | Standard polar | 33892256 | Lucitanib,1TBDMS,isomer #1 | CNC(=O)C1=CC=CC2=CC(OC3=CC=NC4=CC(OCC5(N[Si](C)(C)C(C)(C)C)CC5)=C(OC)C=C34)=CC=C12 | 4371.3 | Semi standard non polar | 33892256 | Lucitanib,1TBDMS,isomer #1 | CNC(=O)C1=CC=CC2=CC(OC3=CC=NC4=CC(OCC5(N[Si](C)(C)C(C)(C)C)CC5)=C(OC)C=C34)=CC=C12 | 4303.2 | Standard non polar | 33892256 | Lucitanib,1TBDMS,isomer #1 | CNC(=O)C1=CC=CC2=CC(OC3=CC=NC4=CC(OCC5(N[Si](C)(C)C(C)(C)C)CC5)=C(OC)C=C34)=CC=C12 | 5463.8 | Standard polar | 33892256 | Lucitanib,1TBDMS,isomer #2 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C(C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N)CC1 | 4330.7 | Semi standard non polar | 33892256 | Lucitanib,1TBDMS,isomer #2 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C(C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N)CC1 | 4143.6 | Standard non polar | 33892256 | Lucitanib,1TBDMS,isomer #2 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C(C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N)CC1 | 5568.0 | Standard polar | 33892256 | Lucitanib,2TBDMS,isomer #1 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C(C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N[Si](C)(C)C(C)(C)C)CC1 | 4513.7 | Semi standard non polar | 33892256 | Lucitanib,2TBDMS,isomer #1 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C(C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N[Si](C)(C)C(C)(C)C)CC1 | 4387.6 | Standard non polar | 33892256 | Lucitanib,2TBDMS,isomer #1 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C(C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N[Si](C)(C)C(C)(C)C)CC1 | 5099.6 | Standard polar | 33892256 | Lucitanib,2TBDMS,isomer #2 | CNC(=O)C1=CC=CC2=CC(OC3=CC=NC4=CC(OCC5(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)CC5)=C(OC)C=C34)=CC=C12 | 4677.2 | Semi standard non polar | 33892256 | Lucitanib,2TBDMS,isomer #2 | CNC(=O)C1=CC=CC2=CC(OC3=CC=NC4=CC(OCC5(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)CC5)=C(OC)C=C34)=CC=C12 | 4517.9 | Standard non polar | 33892256 | Lucitanib,2TBDMS,isomer #2 | CNC(=O)C1=CC=CC2=CC(OC3=CC=NC4=CC(OCC5(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)CC5)=C(OC)C=C34)=CC=C12 | 5201.0 | Standard polar | 33892256 | Lucitanib,3TBDMS,isomer #1 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C(C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)CC1 | 4821.9 | Semi standard non polar | 33892256 | Lucitanib,3TBDMS,isomer #1 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C(C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)CC1 | 4528.9 | Standard non polar | 33892256 | Lucitanib,3TBDMS,isomer #1 | COC1=CC2=C(OC3=CC=C4C(C(=O)N(C)[Si](C)(C)C(C)(C)C)=CC=CC4=C3)C=CN=C2C=C1OCC1(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)CC1 | 4955.5 | Standard polar | 33892256 |
| Show more...
---|